血清 miR-99a 表达在口腔鳞状细胞癌中的诊断和预后价值。

Diagnostic and prognostic value of serum miR-99a expression in oral squamous cell carcinoma.

机构信息

Department of Endodontics, Jinan Stomatological Hospital, Jinan, Shandong, China.

Department of Stomatology, PLA Army General Hospital, Beijing, China.

出版信息

Cancer Biomark. 2018;23(3):333-339. doi: 10.3233/CBM-181265.

DOI:10.3233/CBM-181265

PMID:30223386

Abstract

BACKGROUND

Despite progress in the treatment of oral squamous cell carcinoma (OSCC) over past years, the prognosis for OSCC patients remains dismal. MicroRNA-99a (miR-99a) has been found to involve in the development of many cancer types, but its clinical role in OSCC is unclear.

OBJECTIVE

The aim of this study was to explore the clinical implications of serum miR-99a in OSCC.

METHODS

This study detected serum miR-99a levels in 121 OSCC cases and 55 healthy controls by using quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis.

RESULTS

The data showed that serum miR-99a expression was significantly decreased in OSCC patients compared with normal controls. OSCC patients with low miR-99a expression experienced more frequent poor differentiation and advanced clinical stage. Furthermore, in screening OSCC cases from normal controls, miR-99a could yield a receiver-operating characteristic (ROC) area under the curve (AUC) of 0.911 with 83.6% specificity and 80.2% sensitivity. Notably, patients with high miR-99a expression had longer overall survival and recurrence free survival. Finally, serum miR-99a was identified to be an independent prognostic indicator for OSCC.

CONCLUSIONS

These results suggested that miR-99a might be a valuable marker for the prediction of early detection and prognosis in OSCC.

摘要

背景

尽管近年来口腔鳞状细胞癌（OSCC）的治疗取得了进展，但 OSCC 患者的预后仍然不容乐观。微小 RNA-99a（miR-99a）已被发现参与多种癌症类型的发展，但它在 OSCC 中的临床作用尚不清楚。

目的

本研究旨在探讨血清 miR-99a 在 OSCC 中的临床意义。

方法

本研究采用定量逆转录聚合酶链反应（qRT-PCR）分析检测了 121 例 OSCC 病例和 55 例健康对照者血清 miR-99a 水平。

结果

数据显示，OSCC 患者血清 miR-99a 表达明显低于正常对照组。miR-99a 低表达的 OSCC 患者分化程度较差，临床分期较晚。此外，在从正常对照者中筛选 OSCC 病例时，miR-99a 可产生 0.911 的受试者工作特征（ROC）曲线下面积（AUC），特异性为 83.6%，敏感性为 80.2%。值得注意的是，miR-99a 高表达的患者总生存和无复发生存时间更长。最后，血清 miR-99a 被确定为 OSCC 的独立预后指标。